“An increase in both labeling index and growth fractions by DES exposure was also significantly reversed by co-treatment with luteolin.”
“Cotreatment with luteolin plus DES led to a 64% decrease in the cells in G1 phase (p<0.05), whereas cells in S phase were reduced by 55% (p<0.05) as compared with DES alone.”
“The co-treatment with luteolin significantly reversed the effect of DES on the proliferative activity in all structures of mammary gland.”
“ luteolin co-treatment protected … (T-pot) by DES by increasing the potential doubling time from 22-24 h to 33-38 h. Also, co-treatment with luteolin plus DES … conversion of a small percentage of the gland to Lob 2 and Lob 3 compared to DES treated female rats.”